Product logins

Find logins to all Clarivate products below.


Alzheimer’s Disease – Access & Reimbursement – Access & Reimbursement – Alzheimer’s Disease (US)

Eisai / Biogen’s Leqembi (lecanemab) and Eli Lilly’s Kisunla (donanemab) are vying to capitalize on the potential for a disease-modifying therapy (DMT) in Alzheimer’s disease (AD), and additional anti- monoclonal antibodies (MAbs) (e.g., Roche’s trontinemab) will drive competition and expand treatment choices for patients. Lundbeck / Otsuka’s Rexulti became the first FDA-approved drug to treat agitation in AD, and other novel therapies (i.e., Axsome’s Auvelity) for this condition are advancing. Understanding neurologists’ preferences and expectations for new therapeutics and payers’ receptivity to high-priced brands in this underserved and heavily generic market is key for developers with agents in the large AD pipeline.

Questions answered

  • What is the state of coverage of Leqembi, Kisunla, Rexulti, and other AD brands? What restrictions do payers impose, and how do market access dynamics influence surveyed neurologists’ prescribing?
  • What coverage and uptake are expected for emerging therapies (i.e., Axsome’s Auvelity, BMS’s KarXT, Roche’s trontinemab, Eli Lilly’s remternetug, Eisai / Biogen’s SC lecanemab, Novo Nordisk’s semaglutide)? What clinical and nonclinical differentiators would drive preferential use and coverage terms?
  • What is the state of coverage for AD diagnostics (e.g., PET scans, blood-based biomarkers), and how are physicians using them?

Product description

Leveraging Clarivate’s proprietary data sources and surveys with physicians and payers, Access & Reimbursement provides integrated brand- and disease-level insight on reimbursement dynamics and the impact of payer policy on physician prescribing behavior in the United States. Through detailed analyses of drug coverage, restriction policies, and contracting, as well as payer and prescriber perspectives on key marketed drugs and their receptivity to emerging therapies, this report enables you to:

  • Identify and learn how to overcome roadblocks to market access to best position your brand.
  • Identify key stakeholders and reimbursement drivers and assess the impact that reimbursement decisions have on treatment selection.
  • Evaluate competitor strategies for securing favorable market access terms.

Markets covered: United States

Key drugs: Leqembi, Kisunla, Rexulti, Adlarity, Auvelity

Primary research:

  • Survey of 100 U.S. neurologists
  • Survey of 30 U.S. managed care organization pharmacy and medical directors

Fingertip Formulary: Formulary coverage by Medicare Part D plans covering up to 37.5 million lives

Real-world data: U.S. pharmacy and medical claims data

Key analyses:

  • Reimbursement and contracting
  • Access and prescribing
  • Buy & bill calculations and analysis
  • Couponing and patient affordability
  • Opportunities and challenges for emerging therapies

Related Market Assessment Reports

Report
Epilepsy – Landscape & Forecast – Disease Landscape & Forecast (G7)
Epilepsy is a complex neurological disorder marked by recurrent seizures, affecting approximately 4.7 million people across the major markets, as reported by Clarivate Epidemiology. Given epilepsy…
Report
Biosimilars – Emerging Biosimilars – Emerging Biosimilars Landscape
The Emerging Biosimilars Landscape offers extensive coverage of the global biosimilars development landscape. We track over 722 currently available and novel biosimilar products, detailing…
Report
Psoriasis – Landscape & Forecast – Disease Landscape & Forecast (G7)
The psoriasis therapy market has become increasingly lucrative due to the growing use of targeted agents. The newer IL-17 and IL-23 inhibitors (e.g., Eli Lilly’s Taltz, Johnson & Johnson…
Report
Gastroesophageal Cancer – Geographic Focus: China – China In-Depth – Gastroesophageal cancer
China accounts for nearly half of the cases of gastroesophageal cancer in the world, and its incidence there is expected to increase due to urbanization and an aging population. Current treatment…
Report
Dry and Wet Age-Related Macular Degeneration – Landscape & Forecast – Disease Landscape & Forecast (G7)
Age-related macular degeneration (AMD) is a late-onset retinal disease that diminishes central visual acuity due to photoreceptor degeneration in the macula leading to vision impairment and…